Nevertheless, the approach used enabled us to isolate the effect of acute hyperglycemia from other symptoms or comorbidities of T2DM (e.g., chronic low-grade inflammation, dyslipidaemia, impaired insulin sensitivity and/or secretion, etc.), while also avoiding changes in circulating incretin hormones (e.g., GLP-1) otherwise induced by oral glucose ingestion (71), thus justifying the study design used. The gene discussed is INS; the disease is Hyperglycemia.